Pfizer would do it's shareholders a favor by shutting down its basic research group, saving maybe $5 out the the current $9 Billion it spends annually. (It'll still need the clinical trial group)
It then could use that $5 Bil to purchase its needed research. Pfizer is proof positive that bigger isn't better when it comes to research.
Market Data 
Markets 
AI
